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I read with interest the article by Horii et al. on the predic-
ive ability of B-type natriuretic peptide (BNP) for cardiovascular
vents with reference to renal function [1]. Their study clari-
ed the signiﬁcance of stages in chronic kidney disease (CKD),
hen selecting appropriate biomarkers for mortality and cardio-
ascular events by retrospective cohort study. They conducted
ultiple regression analysis for the prediction of BNP and
mino-terminal proBNP (NT-proBNP), and ﬁnally selected the
eceiver-operating characteristic (ROC) curve analysis to know
he predictive ability of BNP and NT-proBNP for all-cause mor-
ality and composite end point as their statistical methods. As
heir main conclusion, NT-proBNP was superior to BNP in patients
ith CKD stages 4–5. I fundamentally appreciate their study
utcome, but I have two concerns from the statistical view-
oint.
First, I strongly recommend the superiority of NT-proBNP
y the test of ROC curve analysis. Unfortunately, SPSS soft-
are does not present the test of signiﬁcance for ROC
urve analysis between BNP and NT-proBNP. SPSS can only
resent a signiﬁcance of each biomarker against area under
he curve of 0.5. On this point, Sato [2] wrote an editorial
hat mentioned some comments by quoting a reference by
nwaruddin et al. [3]. Anwaruddin et al. used Analyse-it soft-
are (Analyse-it Software, Ltd., Leeds, United Kingdom) to check
he signiﬁcance of ROC curve analysis between two groups.
lternatively, I have an experience of using MedCalc software
MedCalc Software, Ostend, Belgium), including two methods
or detecting statistical difference of area under the ROC curves
4,5].
Second, Horii et al. mentioned that the results of multivari-
te regressions were described in Tables 3 and 4. I suppose that
hese tables presented partial correlation coefﬁcients between
NP or NT-proBNP and several indicators by adjusting other vari-
bles. Apart from these tables, the authors described the equations
f multiple regression analysis for the prediction of NT-proBNP.
hese equations were presented with stratiﬁcation by the stage of
KD. The relationship between BNP and NT-proBNP was closely
ssociated by simple regression especially in CKD stages 1–3,
nd I recommend them excluding BNP from independent vari-
914-5087/$ – see front matter © 2014 Japanese College of Cardiology. Published by Elseables for the prediction of NT-proBNP, and also recommend them
presenting beta values (standardised regression coefﬁcients) by
multiple regression analysis for prediction of BNPby several factors
excluding NT-proBNP from independent variables. These analyses
would present the contributing factors for BNP and NT-proBNP,
and the meaning of these biological indicators would be clariﬁed
with reference to renal function. In these situations, beta values of
independent variables should be precisely evaluated in combina-
tionwith coefﬁcient of determination, whichwas expressed by the
square value of multiple correlation coefﬁcient.
Anyway, the authors intended to clarify the prognostic ability of
BNP and NT-proBNP for mortality and cardiovascular events, and
statistical test of ROC curve analysis would make clear their study
outcome. As there was an intersection of ROC curves between BNP
and NT-proBNP in subjects with CKD stages 4–5, caution should
be paid to accept the superiority of NT-proBNP without the test of
signiﬁcance.
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